Satellos Bioscience (MSCL) 3rd Annual Guggenheim Healthcare Innovation Conference summary

Forazapadin mechanism and clinical programs

• Forazapadin is a small-molecule AAK1 inhibitor intended to improve satellite-cell polarity and muscle regeneration in serious muscle disease, including Duchenne muscular dystrophy (DMD).

• Phase I is complete; Phase II studies include TRAILHEAD in adults with DMD and BASECAMP in children with DMD, with an FSHD program also advancing.

FDA alignment and BASECAMP design

• Following FDA feedback, fat fraction is now BASECAMP’s primary endpoint; the protocol has been amended to incorporate it as an endpoint reasonably likely to predict clinical benefit.

• TRAILHEAD’s first four participants had 1%–6% declines in biceps fat fraction over five months, versus natural-history progression of ~6% per year; these findings informed FDA discussions.

• BASECAMP evaluates boys aged 7–9 using vastus lateralis fat fraction; natural-history data show 10%–20% fat fraction in most children in the relevant age range, with increases of ~10% per year after reaching 10%.

• FDA feedback emphasized larger effects, multiple correlations with clinical measures, and durability across time points; BASECAMP also assesses stride velocity, time to rise, four-stair climb and dynamometry.

• The primary analysis compares all treated participants with placebo; dose-response between 60 mg and 120 mg will also be assessed. Genotype stratification is not planned; age and functional criteria help address variability.

Readouts and development plans

• BASECAMP data are expected in Q1 2027, alongside blinded results and data from participants in the open-label extension; the team aims to assess safety, fat-fraction response and clinical correlations.

• If BASECAMP results are positive, the team plans to move quickly toward younger age groups; existing preclinical work supports further development, and crushed tablets could enable use in younger children, while infants would require formulation work.

• The FDA-cleared FSHD protocol is being activated at sites, with enrollment targeted to start in 2026, completion in 2027 and data potentially available in early 2028; preclinical FLExDUX4 work showed increased muscle function and force generation.

• Funding extends through 2027 and covers TRAILHEAD, BASECAMP and FSHD beyond the BASECAMP readout; additional capital will be needed to develop the pipeline.

• CMC, quality and regulatory preparations for a potential NDA are underway, with CMC targeted to be ready for a 2027 timeframe; high-level results may be shared while discussions with the FDA are ongoing.